What is Hiskast?

Hiskast 4mg drug has the main ingredient is Montelukast Sodium corresponding to Montelukast 4mg and the active ingredient is Mannitol. Hiskast is available as a powder for oral suspension. Hiskast is indicated for children over 2 years old and adults.
Indications to use Hiskast 4mg in the following cases:
Prophylaxis and treatment of chronic bronchial asthma, including prevention of daytime and nighttime asthma symptoms. Treatment of aspirin-sensitive asthmatics. Prophylaxis of exercise-induced bronchospasm. Relieves daytime and nighttime symptoms of seasonal and year-round allergic rhinitis. Contraindicated in patients with hypersensitivity or allergy to any component of the drug Hiskast.

2.1. Dosage Dissolve Hiskast with sufficient amount of filtered water, or use it by mixing with a spoonful of soft food to cool.
The usual dose of Hiskast 4mg: 1 pack/day. No dosage adjustment is required in young children. Children 2-14 years old with asthma and/or allergic rhinitis: 1 sachet/day. The time to take Hiskast does not depend on the meal but mainly on the etiology. Specifically:
Treatment of bronchial asthma: take medicine in the evening. Allergic rhinitis: the timing of administration depends on the needs of each patient. Patients with both asthma and allergic rhinitis: take the drug in the evening. Patients should be evaluated after 2 to 4 weeks for response to treatment with Hiskast. Continue to use the medicine even though your asthma symptoms have improved, and continue taking it during periods of severe asthma.
Currently, research on the effectiveness of treatment in children under 2 years old is limited and the drug should not be used for this population.
No dose adjustment is required for patients with renal impairment, or mild to moderate hepatic impairment.
2.2. Overdose and Management Clinical and laboratory findings were observed consistent with the safety profile in adult and pediatric patients. There were no adverse experiences in the majority of overdose reports.
In the majority of reports of overdose of the drug Hiskast, no adverse reactions to the body were encountered. Possible overdose symptoms are similar to the safety profile of Montelukast. Examples include headache, increased agitation, abdominal pain, thirst, nausea, vomiting.
There are no specific recommendations for treatment of overdose with Montelukast. At present, it is not clear whether Montelukast can be eliminated by hemodialysis or by peritoneal dialysis.

Undesirable effects when using Hiskast drugs are usually mild, rarely occur and do not require discontinuation of the drug.
Upper respiratory tract infection. Immune system: hypersensitivity reactions including anaphylaxis, very rarely hepatic eosinophilic infiltration. Skin and subcutaneous tissue: rash, angioedema, pruritus, urticaria, erythema multiforme. CNS: nightmares, insomnia, hallucinations, anxiety, agitation including aggressive behavior, hyperactivity, paresthesia/hypoesthesia and very rarely convulsions. More rarely, memory impairment, attention disorder. Gastrointestinal: dyspepsia, dry mouth, nausea, vomiting, diarrhea, elevated liver enzymes (AST and ALT), hepatitis. Musculoskeletal: uncommon, myalgia, muscle cramps, arthralgia. Some other side effects: increased likelihood of bleeding, bleeding, bleeding under the skin, palpitations, bedwetting in children.
Please inform your doctor if you experience unwanted effects when using Hiskat.

The efficacy of Montelukast has not been established in the treatment of acute asthma attacks. Patients should be advised not to use oral Montelukast for acute asthma attacks and that other appropriate acute asthma medication should be available at all times.
Montelukast should not be abruptly substituted for inhaled or oral corticosteroids. When dose reduction or withdrawal of systemic corticosteroids in patients receiving other anti-asthmatics, including leukotriene receptor antagonists, the following rare events may develop: eosinophilia, clinically manifest systemic vasculitis consistent with Churg-Strauss syndrome. Although it is not possible to exclude as well as determine whether Leukotriene receptor antagonists are involved in the occurrence of Churg - Strauss syndrome or not. However, caution and close clinical monitoring are still needed when reducing the dose of systemic corticosteroids in patients receiving Montelukast. Use caution and reassess regimen if patient develops eosinophilia, worsening respiratory symptoms, cardiac complications, or neurological symptoms.
Use caution in patients with neuropsychiatric conditions due to the risk of undesirable effects. Carefully assess the risks and benefits of continuing treatment with Montelukast if the patient develops neuropsychiatric adverse events.
Pregnancy: There are no adequate data on the use of the drug in pregnant women. Therefore, use Hiskast only when absolutely necessary.
Lactating women: studies in rats have shown that Montelukast is excreted in human milk. The drug should be used with caution in this population, after fully assessing the risks and benefits to the mother.

Hiskast can be used concurrently with other drugs in the prevention and treatment of chronic bronchial asthma, allergic rhinitis.
Recommended therapeutic doses of Hiskast generally do not significantly affect the pharmacokinetics of the following drugs: Prednisone, Prednisolone, Theophylline, oral contraceptives, Terfenadine, Digoxin and Warfarin.
Hiskast 4mg drug belongs to the group of effects on the respiratory tract. Hiskast is used in the prevention and treatment of chronic bronchial asthma. To ensure effective treatment and avoid unwanted side effects, patients need to carefully read the instructions before use and consult a doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.